Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v10-EN | Version v6-EN | |
---|---|---|
Language | English | English |
Date Updated | 2025-05-01 | 2025-04-30 |
Drug Identification Number | 00397466 | 00397466 |
Brand name | CYSTO-CONRAY II | CYSTO-CONRAY II |
Common or Proper name | Iothalamate Meglumine Injection 17.2% w/v | Iothalamate Meglumine Injection 17.2% w/v |
Company Name | LIEBEL-FLARSHEIM COMPANY LLC | LIEBEL-FLARSHEIM COMPANY LLC |
Ingredients | IOTHALAMATE MEGLUMINE | IOTHALAMATE MEGLUMINE |
Strength(s) | 172MG | 172MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | URETHRAL URETHRAL | URETHRAL URETHRAL |
Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
Additional packaging sizes | 250 mL | 250 mL |
ATC code | V08AA | V08AA |
ATC description | X-RAY CONTRAST MEDIA, IODINATED | X-RAY CONTRAST MEDIA, IODINATED |
Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
Anticipated start date | 2023-08-05 | 2023-08-05 |
Actual start date | ||
Estimated end date | ||
Actual end date | 2025-04-30 | 2025-04-30 |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | Marketing status is changed to Dormant. Product has not been marketed in last 12 months. | Marketing status is changed to Dormant. Product has not been marketed in last 12 months. |
Health Canada comments |